EuroPCR 2024: Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
Clinical results show statistically significant benefit with DynamX bioadaptor over Resolute Onyx at two years, including a 65% reduction in TLF rate (1.9% versus 5.5%; p=0.046), driven by low adverse events across all components of the composite endpoint with DynamX compared to DES.
Elixir Medical To Announce Data from Three Platforms Designed to Transform Cardiovascular Disease Treatment at EuroPCR 2024, Including Two Late-Breakers
Researchers will present results from the BIOADAPTOR RCT, studying DynamX® bioadaptor vs. DES; PINNACLE I, which reviews the novel LithiX Hertz Contact Intravascular Lithotripsy technology; and one-year results from DESyne BDS Plus RCT, a study of the novel TRx site-specific antithrombotic therapeutic.
King Fahad Armed Forces Hospital Begins Trial of New Bioadaptive Angioplasty Procedure for Heart Disease Treatment
King Fahad Armed Forces Hospital is the first in the Kingdom of Saudi Arabia to begin clinical research and offer a new type of angioplasty procedure with the DynamX® Bioadaptor, a novel coronary implant designed to restore vessel function in patients with coronary artery disease (CAD).
Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease
Elixir Medical today announced it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its DynamX® BTK System.
TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir Medical announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus versus a second-generation, durable polymer drug-eluting stent (DES).
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
Elixir Medical will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
“Our submission for approval in Japan is an exciting milestone for the company and industry,” said Motasim Sirhan, CEO of Elixir Medical.
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
The trial, which includes 2,400 patients from 20 sites across Sweden, compares DynamX Bioadaptor to Resolute Onyx.
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s Dynamx Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
Clinical data demonstrates Dynamx Bioadaptor restores vessel motion and function with better effectiveness than competitors.
Elixir Medical Expands Leadership Team with Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing
Nepogodiev possesses more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide.